Case Report: Upadacitinib for the treatment of MDA5-antibody-positive dermatomyositis complicated by RP-ILD
Background Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is a subtype of idiopathic inflammatory myopathies with the poorest prognosis. The clinical course may be further complicated by respiratory failure, sepsis, or secondary hemophagocytic syndrome during the course of the disease, leading to a significantly higher mortality rate. Conventional treatment strategies include glucocorticoids combined with immunosuppression, while newer targeted therapies such as JAK inhibitors and other biologics are increasingly being used in refractory cases. Case summary A 56-year-old woman with anti-MDA5 antibody-positive dermatomyositis complicated by rapidly progressive interstitial lung disease initially achieved clinical stabilization after treatment with high-dose glucocorticoid pulse therapy combined with human immunoglobulin infusion, with the addition of tacrolimus and upadacitinib. However, shortly thereafter, her serum ferritin levels progressively rose and her blood cell counts progressively declined. She was diagnosed with macrophage activation syndrome (MAS) according to the 2016 EULAR/ACR/PRINTO classification criteria for MAS complicating systemic juvenile idiopathic arthritis. MAS is a subtype of secondary haemophagocytic lymphohistiocytosis (sHLH) and belongs to the HLH spectrum of diseases occurring in the context of rheumatic diseases. In the rheumatology literature, MAS and secondary HLH/haemophagocytic syndrome (HPS) are often regarded as overlapping and essentially equivalent disease entities, sharing a common basis of uncontrolled immune activation and a cytokine storm. Following the addition of 200 mg of a fully human anti-interleukin-1β (IL-1β) monoclonal antibody and intermittent plasma exchange, her blood cell counts and ferritin levels gradually normalized, her clinical condition improved, and she was successfully discharged. At follow-up, laboratory parameters remained stable. Conclusion For patients with anti-MDA5 antibody-positive dermatomyositis complicated by rapidly progressive interstitial lung disease, Upadacitinib may represent a valuable treatment option. Targeted therapy with anti-IL-1β monoclonal antibodies may serve as an effective rescue therapy for patients with macrophage activation syndrome.
Authors
- Yong Xu (ORCID: https://orcid.org/0000-0001-5968-8127)
- Jian Hao (ORCID: https://orcid.org/0000-0001-7637-009X)
- Tong Gai
- Xiuhua Wu
- Xin Li
- Muhao Li
- Rongying Lu
Institutions
- Tianjin Medical University General Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fmed.2026.2004225
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00